Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase.

Biometal Science Laboratory, RIKEN SPring-8 Center, Harima Institute, Hyogo 679-5148, Japan.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 03/2006; 103(8):2611-6. DOI: 10.1073/pnas.0508996103
Source: PubMed

ABSTRACT Human indoleamine 2,3-dioxygenase (IDO) catalyzes the cleavage of the pyrrol ring of L-Trp and incorporates both atoms of a molecule of oxygen (O2). Here we report on the x-ray crystal structure of human IDO, complexed with the ligand inhibitor 4-phenylimidazole and cyanide. The overall structure of IDO shows two alpha-helical domains with the heme between them. A264 of the flexible loop in the heme distal side is in close proximity to the iron. A mutant analysis shows that none of the polar amino acid residues in the distal heme pocket are essential for activity, suggesting that, unlike the heme-containing monooxygenases (i.e., peroxidase and cytochrome P450), no protein group of IDO is essential in dioxygen activation or proton abstraction. These characteristics of the IDO structure provide support for a reaction mechanism involving the abstraction of a proton from the substrate by iron-bound dioxygen. Inactive mutants (F226A, F227A, and R231A) retain substrate-binding affinity, and an electron density map reveals that 2-(N-cyclohexylamino)ethane sulfonic acid is bound to these residues, mimicking the substrate. These findings suggest that strict shape complementarities between the indole ring of the substrate and the protein side chains are required, not for binding, but, rather, to permit the interaction between the substrate and iron-bound dioxygen in the first step of the reaction. This study provides the structural basis for a heme-containing dioxygenase mechanism, a missing piece in our understanding of heme chemistry.


Available from: Tomoya Hino, Jun 04, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: A cytokine-inducible extrahepatic human indoleamine 2,3-dioxygenase (hIDO1) catalyzes the first step of the kynurenine pathway. Immunosuppressive activity of hIDO1 in tumor cells weakens host T-cell immunity, contributing to the progression of cancer. Here we report on enzyme kinetics and catalytic mechanism of hIDO1, studied at varied levels of dioxygen (O2) and l-tryptophan (l-Trp). Using a cytochrome b5-based activating system, we measured the initial rates of O2 decay with a Clark-type oxygen electrode at physiologically-relevant levels of both substrates. Kinetics was also studied in the presence of two substrate analogs: 1-methyl-l-tryptophan and norharmane. Quantitative analysis supports a steady-state rather than a rapid equilibrium kinetic mechanism, where the rates of individual pathways, leading to a ternary complex, are significantly different, and the overall rate of catalysis depends on contributions of both routes. One path, where O2 binds to ferrous hIDO1 first, is faster than the second route, which starts with the binding of l-Trp. However, l-Trp complexation with free ferrous hIDO1 is more rapid than that of O2. As the level of l-Trp increases, the slower route becomes a significant contributor to the overall rate, resulting in observed substrate inhibition. Copyright © 2015. Published by Elsevier Inc.
    Archives of Biochemistry and Biophysics 02/2015; 570. DOI:10.1016/ · 3.04 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Indoleamine 2,3-dioxygenase (IDO) is emerging as an important new therapeutic drug target for the treatment of cancer characterized by pathological immune suppression. IDO catalyzes the rate-limiting step of tryptophan degradation along the kynurenine pathway. Reduction in local tryptophan concentration and the production of immunomodulatory tryptophan metabolites contribute to the immunosuppressive effects of IDO. Presence of IDO on dentritic cells in tumor-draining lymph nodes leading to the activation of T cells toward forming immunosuppressive microenvironment for the survival of tumor cells has confirmed the importance of IDO as a promising novel anticancer immunotherapy drug target. On the other hand, Withaferin A (WA) - active constituent of Withania Somnifera ayurvedic herb has shown to be having a wide range of targeted anticancer properties. In the present study conducted here is an attempt to explore the potential of WA in attenuating IDO for immunotherapeutic tumor arresting activity and to elucidate the underlying mode of action in a computational approach. Our docking and molecular dynamic simulation results predict high binding affinity of the ligand to the receptor with up to -11.51 kcal/mol of energy and 3.63 nM of IC50 value. Further, de novo molecular dynamic simulations predicted stable ligand interactions with critically important residues SER167; ARG231; LYS377, and heme moiety involved in IDO's activity. Conclusively, our results strongly suggest WA as a valuable small ligand molecule with strong binding affinity toward IDO.
    Journal of biomolecular Structure & Dynamics 02/2015; DOI:10.1080/07391102.2015.1004834 · 2.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Dendritic cells (DCs) are antigen presenting cells that activate T cells and determine the outcome of immune response. In addition to their important function in defense against pathogens, DCs are increasingly recognized as playing a crucial role in the regulation of immune tolerance. Plasticity of DCs with different maturity status and functions enable them to be exploited as potential cell-based therapy to restore immune tolerance in autoimmune diseases. Various ex vivo methods have been developed to generate stable tolerogenic DCs that are able to induce and maintain regulatory T cell homeostasis. The beneficial effect of tolerogenic DCs have been studied in murine autoimmune models with promising results. Systemic lupus erythematosus (SLE) is a prototypic multi-systemic autoimmune disease characterized by autoantibody production and deposition of immune complexes in organs. There are evidences that dysregulated DCs play a pivotal role in the initiation and perpetuation of lupus disease. Peripheral blood monocytes in SLE patients were found to have active phenotype with accelerated differentiation into DCs efficient in antigen presentation. Plasmacytoid DCs in SLE patients produce high levels of interferon-alpha, the signature cytokine of this disease, that cause a positive feedback loop in the amplification of activation of innate and adaptive immunity. Furthermore, manipulation of DCs via toll-like receptor knockout in a murine lupus model leads to alteration in disease severity and survival. Thus, tolerogenic DCs may appear as a potential cell-based therapeutic option in SLE.
    International Journal of Rheumatic Diseases 12/2014; 18(2). DOI:10.1111/1756-185X.12532 · 1.77 Impact Factor